ExtendNS Background Information
A study was designed as a double-blinded placebo control trial on 110 cervical cancer patients. Patients received either Extend or placebo in a randomized manner, to ingest 2 tabs tid w/meals, 4 days before their treatment with radiation. A cobalt-60 teletherapy machine was used in this study. Irradiation dose was 45 to 50 Gray given over a period of 4.5 to 5.0 weeks. Patients continued taking Extend or placebo during the whole treatment period. Once the biochemical data and clinical observations were completed, these were analyzed and found to give the results as presented below.
|
Body Wt |
Eosinophil |
Hemoglobin |
Lymphocytes |
Neutrophils |
WBC |
Platelet |
Loss of body weight (cachexia) and appetite (anorexia) is a serious problem usually encountered during the treatment of cancer patients with chemo- and/or radiotherapies. Such condition was obviously observed in the control patients in this study whose mean body weight decreased to 36.7±5.5 kg from a pretreatment body weight of 41.1±4.4 kg. Statistically this is a significant (p=0.06) weight loss over a period of 4 to 5 weeks. Extend supplemented patients, on the other hand, did not show any reduction in their body weight, rather some of them gained some weight, albeit not significantly. Stability of body weight, particularly during the therapy, is highly desirable.
Bone marrow toxicity (myelosuppression) due to chemo-and/or radiotherapies many times poses life-threatening problem to the cancer patients by making them more prone to many opportunistic diseases. In fact, antineoplastic therapy-associated toxicities may be the secondary factors of patients mortality. Moreover, success of any anticancer therapy could be dependent on immuno-compatibility, which may be severely compromised in malnourished patients and/or may be altered due to the therapeutic modalities. The measured mean value of platelet count (PC), i.e. the bone marrow status, in the Extend supplemented patients in this study was found to be enhanced from 2.6±0.10 x 104 Cu mm to 3.9±0.3 x 104 Cu mm, which is significantly higher within the group and between the groups, i.e. control versus supplemented. This therefore indicated that Extend not only prevented the bone marrow depletion, rather increased it significantly.
Apart from the above studies, there were several anecdotal observations on the effects of Extend on several other cancer patients. At least two patients with lung cancer (small cell carcinoma) and 5 patients with breast cancer, who took this product during their chemo- and/or radiotherapies, did not show any deterioration of their health and in fact, all of them are disease free today. Extend is, therefore, intended to work as an adjuvant to any cancer therapies.
It is very obvious from the above observations that Extend could be useful for any diseases with immune disorders, particularly disease like aplastic anemia. In fact, one patient, who was dying from this disease in Bangladesh, took this product and now the patient is living a normal life.
Place your for ExtendNS online now.
> ExtendNS and effects on cancer patients in international clinical trial
> Dosage information
